Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals, a division of Wyeth, has initiated the Intoract study, a randomized, open-label, Phase IIIb study comparing Torisel plus Avastin versus Avastin plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma.
Subscribe to our email newsletter
Wyeth Research is conducting the Intoract study with the support and assistance of Roche and Genentech. The primary end point of the Intoract study is independently assessed progression-free survival (PFS) of patients in all risk groups. Secondary end points include safety, investigator-assessed PFS, independently assessed objective response rate and overall survival.
Joseph Camardo, senior vice president of global medical affairs at Wyeth Pharmaceuticals, said: “In the Intoract study, we hope to learn more about whether combining Torisel with other agents in the first-line setting may further improve outcomes for patients with this devastating disease.”